News
For my remarks, I will review some of our key performance drivers, then briefly discuss some pipeline advances ... If approved in RVO, EYLEA HD would be the first and only treatment that can ...
Despite treatment advances, MM is not curable and while current treatments ... including Regeneron's agreements with Sanofi and Bayer (or their respective affiliated companies, as applicable) to be ...
Despite treatment advances, MM is not curable and while current ... including Regeneron’s agreements with Sanofi and Bayer (or their respective affiliated companies, as applicable) to be ...
German drugmaker Bayer on Friday won an endorsement by the European Medicines Agency to extend the intervals between shots of ...
Bayer A.G. ( OTCPK:BAYZF) ( OTCPK:BAYRY) said that an advisory panel of the European Medicines Agency (EMA), endorsed the ...
CHICAGO (Reuters) - Bayer is exiting the seed treatment equipment business in the United States to help the company's finances, according to an email sent to customers that was seen by Reuters on ...
CHICAGO (Reuters) - Bayer is exiting the seed treatment equipment business in the United States to help the company's finances, according to an email sent to customers that was seen by Reuters on ...
Novartis is launching a head-to-head trial of its experimental brolucizumab therapy for age-related macular degeneration (AMD) against Bayer/Regeneron’s Eylea, the market leader. The TALON trial ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback